Liver FibrosisNAFLDNCT04561804
NAFLD and Liver Fibrosis in Obese Adolescents
An observational study of Liver Fibrosis and Liver Steatosis, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
Trial summary
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the United States. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Liver Fibrosis, Liver Steatosis, Weight Loss
- What is being tested?
- laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Dec 2018to 1 Dec 2019
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Child, Adult, Older adult
Study population: We prospectively recruited all children and adolescents (age 7-18 years) with obesity who were admitted to the Obesity clinic at Dana-Dwek Children's Hospital of the Tel Aviv Medical Center between December 1, 2018, and December 1, 2019. All children with a BMI >95 percentile for age were included in the study.
Who may be able to join
None listed.
Who cannot join
- Children that are known to suffer from genetic/metabolic disorders that can cause steatosis- Wilson disease, hypothyroidism, autoimmune hepatitis, Alpha 1 antitrypsin.
- Children infected with HBV or HCV, HAV.
- Children that use medications that can cause liver steatosis- amiodarone, MTX, Corticosteroids
- Children with significant ethanol consumption ->10 gr per day for women and >20gr per day for men.
- Pregnant women.
- Obesity due to syndromes or monogenic disease
- General withdraw criteria:
- If the participant withdraws his consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: NAFLD and Liver Fibrosis in Obese Adolescents Undergoing Weight Loss by Surgery or Life Style Intervention
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the United States. NAFLD can result in progressive fibrosis and lead to end-stage liver disease. Best practices in management of pediatric NAFLD are not clearly defined.
Our aim is to clarify the natural history of NAFLD in obese children after weight loss surgery compare to lifestyle intervention. Our secondary aim is to investigate the added value of elastography for the screening and diagnosis of NASH with fibrosis.
Read the detailed description
The study population will consist of obese adolescents, male and female, age 7-18, that will go through weight loss reduction surgery (WLS) in the Obesity Clinic at Tel Aviv Sourasky Medical Center. A control group matched for age and sex will consist of patients that will go through conventional treatment (see below) at the Obesity Clinic in Dana Dwek Children's Hospital.
Written informed consent form will be signed by the participant before enrollment Patient Population Patients with a diagnosed primary liver disease (autoimmune liver disease, metabolic liver disease, Wilson's disease, alpha 1 antitrypsin deficiency), patients treated with medications known to induce steatosis (such as valproate, amiodarone or prednisone), and patients with hepatic virus infections or history of parenteral nutrition were excluded from the study.
Study Design and measurements This clinical trial aims to asses the effect of bariatric surgery and dietary intervention on hepatic fibrosis in obese pediatric population with NAFLD (Clinical Trial Registration- MOH_2017-06-07_000470, https://my.health.gov.il/CliniTrials/Pages/MOH_2017-06-07_000470.aspx). At the initial visit, data were collected on socioeconomic parameters, lifestyle, birth details, and medical, family, and social histories. All patients underwent anthropometric measures (height, weight and BMI) and a physical examination focused on obesity-related conditions. Laboratory evaluation included liver enzyme profile, lipid profile, glucose, insulin, and HbA1C. Liver fibrosis was estimated by Shearwave elastography (Supersonic) and categorized into 4 levels, F0-F4, according to liver stiffness (measured by kPa), as recently demonstrated elsewhere [9]. Liver steatosis was calculated by a hepatorenal index (HRI) and divided into 3 levels of severity. All measurements were taken by a single experienced radiologist (MW), who was blinded to the results of other parameters of the patients. A multidisciplinary team included a gastroenterologist, hepatologists, a registered dietitian (RD) and a psychologist. All participants received nutritional recommendations (see below) and general recommendation for a healthy lifestyle (regular engagement in daily physical activity and reduction of screen time). Compliance with the dietary guideline was reviewed by a RD on a biweekly basis with a 3-day food questionnaire (2 weekdays and 1 day of the weekend). Blood tests and elastography were repeated after 3 months of intervention.
Determination of the BMI percentiles for age and gender was based on WHO growth charts. "Obesity" was defined as a BMI >95th percentile . Abnormal glucose metabolism included taking a hypoglycemic medication or having an elevated homeostatic model assessment index of insulin resistance, glucose, or HBA1c. Hypertriglyceridemia and hypercholesterolemia were defined as a serum level >95 percentile for age and sex. Hypertension was diagnosed as systolic and/or diastolic blood pressure ≥95 percentile for age and sex. Patients with clinical suspicion of obstructive sleep apnea (OSA) were diagnosed by polysomnography that was conducted by the hospital's sleep specialists. Socioeconomic status was defined according to parents' years of education.
The dietary intervention The participants received nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet was composed of carbohydrates (CHO;30-40%), fats (35-50%), and proteins (20-25%), and was tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings was determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants were not instructed to restrict calories, but to reduce carbohydrate based on their glycemic load. High glycemic index (GI) carbohydrate intake (refined grains, potatoes, sweet and salted snacks and sugar sweetened beverages) was completely restricted, low GI carbohydrates (non-starchy vegetables, legumes, nuts,) were allowed and some low /moderate GI carbohydrate were allowed but limited such as fruits and whole grain bread.
The subjects were instructed about appropriate food choices, and each participant was provided a diet information booklet containing food list, sample menus and recipes
Statistical Analyses Descriptive statistics were examined for all variables. Continuous variables were expressed as median with interquartile range (IQR) when they were not normally distributed and as mean ± standard deviation (SD) for normally distributed variables. Categorical variables were presented as number and percentage. Categorical variables were compared by the McNamer test and continuous and ordinal variables by the Wilcoxon test. The Fischer test was used when the McNamer test was not applicable for some variables. The Pearson correlation and simple linear regression analysis were performed to examine bivariate associations between fibrosis and metabolic and nutritional parameters. The Wilcoxon signed rank test was applied to compare the difference between steatosis, fibrosis, and metabolic parameters between the 2 time points (baseline and 3-month follow-up). A P level <0.05 was considered statistically significant. All statistical tests were 2-sided. The statistical analysis was performed with SPSS (IBM SPSS statistics, version 22, IBM Corp. Armonk, NY, USA, 2013.).
- Conditions
- Liver Fibrosis, Liver Steatosis, Weight Loss
- Being tested
- laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)
- Medical subject headings
- Liver Cirrhosis, Fatty Liver, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)Procedure or surgery
Also called Dietary intervention
The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.
The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes
| Study group | Role | What they receive |
|---|---|---|
| LISESTYLE INTERVENTION | LOW CARB LOW GLYCEMIC LOAS DIET | |
| WEGHT LOSS SURGERY | SLEEVE OR MINBYPASS SURGERY Receives: Procedure: laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB) |
What is being measured
The primary outcome is the main question the study is designed to answer.
change in liver fibrosis
Liver fibrosis will be estimated by Shearwave elastography (Supersonic) and categorized into 4 levels, F0-F4, according to liver stiffness
Measured: 3 and 6 months
Secondary outcomes (2)
change in liver steatosis
Liver steatosis will be calculated by a hepatorenal index (HRI) and divided into 3 levels of severity
Measured: 3 and 6 months
weight reduction
BMI measurements
Measured: 3 and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2020
- Study start1 Dec 2018
- Primary completion1 Dec 2019
- Study completion1 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Liver FibrosisStudies of the same condition, open and under way.
- More trials run by Tel-Aviv Sourasky Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Sponsor type
- Other government
- Responsible party
- Principal investigator, michal roll, Tel-Aviv Sourasky Medical Center
- Investigators
- sHLOMI Cohen, prof, Principal investigator, Dana Dwek Children Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04561804
- Sponsor's protocol ID
- 0097-17-TLV
- Acronym
- NAFLD
- Status last verified
- Sep 2020
- First submitted
- 17 Sep 2020
- Last updated
- 24 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data will be provided to other researchers upon a reasonable request
Publications
Moran-Lev H, Cohen S, Webb M, Yerushalmy-Feler A, Amir A, Gal DL, Lubetzky R. Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study. BMC Pediatr. 2021 Sep 3;21(1):385. doi: 10.1186/s12887-021-02839-1.
PubMed 34479517
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NAFLD and Liver Fibrosis in Obese Adolescents Undergoing Weight Loss by Surgery or Life Style Intervention
- ClinicalTrials.gov ID
- NCT04561804
- Acronym / sponsor ID
- NAFLD / 0097-17-TLV
- Conditions
- Liver Fibrosis, Liver Steatosis, Weight Loss
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterOther government
- Study start
- 1 Dec 2018 (actual)
- Primary completion
- 1 Dec 2019 (actual)
- Study completion
- 1 Dec 2019 (actual)
- First posted
- 24 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the United States. NAFLD can result in progressive fibrosis and lead to end-stage liver disease. Best practices in management of pediatric NAFLD are not clearly defined.
Our aim is to clarify the natural history of NAFLD in obese children after weight loss surgery compare to lifestyle intervention. Our secondary aim is to investigate the added value of elastography for the screening and diagnosis of NASH with fibrosis.
Detailed description
The study population will consist of obese adolescents, male and female, age 7-18, that will go through weight loss reduction surgery (WLS) in the Obesity Clinic at Tel Aviv Sourasky Medical Center. A control group matched for age and sex will consist of patients that will go through conventional treatment (see below) at the Obesity Clinic in Dana Dwek Children's Hospital.
Written informed consent form will be signed by the participant before enrollment Patient Population Patients with a diagnosed primary liver disease (autoimmune liver disease, metabolic liver disease, Wilson's disease, alpha 1 antitrypsin deficiency), patients treated with medications known to induce steatosis (such as valproate, amiodarone or prednisone), and patients with hepatic virus infections or history of parenteral nutrition were excluded from the study.
Study Design and measurements This clinical trial aims to asses the effect of bariatric surgery and dietary intervention on hepatic fibrosis in obese pediatric population with NAFLD (Clinical Trial Registration- MOH_2017-06-07_000470, https://my.health.gov.il/CliniTrials/Pages/MOH_2017-06-07_000470.aspx). At the initial visit, data were collected on socioeconomic parameters, lifestyle, birth details, and medical, family, and social histories. All patients underwent anthropometric measures (height, weight and BMI) and a physical examination focused on obesity-related conditions. Laboratory evaluation included liver enzyme profile, lipid profile, glucose, insulin, and HbA1C. Liver fibrosis was estimated by Shearwave elastography (Supersonic) and categorized into 4 levels, F0-F4, according to liver stiffness (measured by kPa), as recently demonstrated elsewhere [9]. Liver steatosis was calculated by a hepatorenal index (HRI) and divided into 3 levels of severity. All measurements were taken by a single experienced radiologist (MW), who was blinded to the results of other parameters of the patients. A multidisciplinary team included a gastroenterologist, hepatologists, a registered dietitian (RD) and a psychologist. All participants received nutritional recommendations (see below) and general recommendation for a healthy lifestyle (regular engagement in daily physical activity and reduction of screen time). Compliance with the dietary guideline was reviewed by a RD on a biweekly basis with a 3-day food questionnaire (2 weekdays and 1 day of the weekend). Blood tests and elastography were repeated after 3 months of intervention.
Determination of the BMI percentiles for age and gender was based on WHO growth charts. "Obesity" was defined as a BMI >95th percentile . Abnormal glucose metabolism included taking a hypoglycemic medication or having an elevated homeostatic model assessment index of insulin resistance, glucose, or HBA1c. Hypertriglyceridemia and hypercholesterolemia were defined as a serum level >95 percentile for age and sex. Hypertension was diagnosed as systolic and/or diastolic blood pressure ≥95 percentile for age and sex. Patients with clinical suspicion of obstructive sleep apnea (OSA) were diagnosed by polysomnography that was conducted by the hospital's sleep specialists. Socioeconomic status was defined according to parents' years of education.
The dietary intervention The participants received nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet was composed of carbohydrates (CHO;30-40%), fats (35-50%), and proteins (20-25%), and was tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings was determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants were not instructed to restrict calories, but to reduce carbohydrate based on their glycemic load. High glycemic index (GI) carbohydrate intake (refined grains, potatoes, sweet and salted snacks and sugar sweetened beverages) was completely restricted, low GI carbohydrates (non-starchy vegetables, legumes, nuts,) were allowed and some low /moderate GI carbohydrate were allowed but limited such as fruits and whole grain bread.
The subjects were instructed about appropriate food choices, and each participant was provided a diet information booklet containing food list, sample menus and recipes
Statistical Analyses Descriptive statistics were examined for all variables. Continuous variables were expressed as median with interquartile range (IQR) when they were not normally distributed and as mean ± standard deviation (SD) for normally distributed variables. Categorical variables were presented as number and percentage. Categorical variables were compared by the McNamer test and continuous and ordinal variables by the Wilcoxon test. The Fischer test was used when the McNamer test was not applicable for some variables. The Pearson correlation and simple linear regression analysis were performed to examine bivariate associations between fibrosis and metabolic and nutritional parameters. The Wilcoxon signed rank test was applied to compare the difference between steatosis, fibrosis, and metabolic parameters between the 2 time points (baseline and 3-month follow-up). A P level <0.05 was considered statistically significant. All statistical tests were 2-sided. The statistical analysis was performed with SPSS (IBM SPSS statistics, version 22, IBM Corp. Armonk, NY, USA, 2013.).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LISESTYLE INTERVENTION | – | –LOW CARB LOW GLYCEMIC LOAS DIET |
| WEGHT LOSS SURGERY | – | Procedure: laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)SLEEVE OR MINBYPASS SURGERY |
Who may qualify
- Age groups
- Child, Adult, Older adult
- Study population
- We prospectively recruited all children and adolescents (age 7-18 years) with obesity who were admitted to the Obesity clinic at Dana-Dwek Children's Hospital of the Tel Aviv Medical Center between December 1, 2018, and December 1, 2019. All children with a BMI >95 percentile for age were included in the study.
Key inclusion criteria (0 listed)
Key exclusion criteria (8 listed)
- Children that are known to suffer from genetic/metabolic disorders that can cause steatosis- Wilson disease, hypothyroidism, autoimmune hepatitis, Alpha 1 antitrypsin.
- Children infected with HBV or HCV, HAV.
- Children that use medications that can cause liver steatosis- amiodarone, MTX, Corticosteroids
- Children with significant ethanol consumption ->10 gr per day for women and >20gr per day for men.
- Pregnant women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)Also: Dietary interventionThe participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load. The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes | Procedure or surgery | WEGHT LOSS SURGERY |
Primary outcome
change in liver fibrosis
Time frame: 3 and 6 months
Liver fibrosis will be estimated by Shearwave elastography (Supersonic) and categorized into 4 levels, F0-F4, according to liver stiffness
2 secondary outcomes
change in liver steatosis
Time frame: 3 and 6 months
weight reduction
Time frame: 3 and 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2020.
- Derived from this study: PubMed 34479517Moran-Lev H, Cohen S, Webb M, Yerushalmy-Feler A, Amir A, Gal DL, Lubetzky R. Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study. BMC Pediatr. 2021 Sep 3;21(1):385. doi: 10.1186/s12887-021-02839-1.
- Individual participant dataSharing planned: No. The data will be provided to other researchers upon a reasonable request
Related trials for Liver Fibrosis
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal Bleeding in Cirrhosis
Cirrhosis, Portal Hypertension Related to Cirrhosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
sHLOMI Cohen, prof principal investigator
Dana Dwek Children Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Fibrosis and Liver Steatosis, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in liver fibrosis (time frame: 3 and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04561804, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2020.